27 results on '"Jaffar Ali Raza"'
Search Results
2. Survivable Robotic Control through Guided Bayesian Policy Search with Deep Reinforcement Learning.
- Author
-
Sayyed Jaffar Ali Raza, Apan Dastider, and Mingjie Lin
- Published
- 2021
- Full Text
- View/download PDF
3. Safe Locomotion Within Confined Workspace using Deep Reinforcement Learning.
- Author
-
Apan Dastider, Sayyed Jaffar Ali Raza, and Mingjie Lin
- Published
- 2021
- Full Text
- View/download PDF
4. Developmentally Synthesizing Earthworm-Like Locomotion Gaits with Bayesian-Augmented Deep Deterministic Policy Gradients (DDPG).
- Author
-
Sayyed Jaffar Ali Raza, Apan Dastider, and Mingjie Lin
- Published
- 2020
- Full Text
- View/download PDF
5. Survivable Hyper-Redundant Robotic Arm with Bayesian Policy Morphing.
- Author
-
Sayyed Jaffar Ali Raza, Apan Dastider, and Mingjie Lin
- Published
- 2020
- Full Text
- View/download PDF
6. Constructive Policy: Reinforcement Learning Approach for Connected Multi-Agent Systems.
- Author
-
Sayyed Jaffar Ali Raza and Mingjie Lin
- Published
- 2019
- Full Text
- View/download PDF
7. Real-World Modeling of a Pathfinding Robot Using Robot Operating System (ROS).
- Author
-
Sayyed Jaffar Ali Raza, Nitish A. Gupta, Nisarg Chitaliya, and Gita Reese Sukthankar
- Published
- 2018
8. Developmentally Synthesizing Earthworm-Like Locomotion Gaits with Bayesian-Augmented Deep Deterministic Policy Gradients (DDPG)
- Author
-
Mingjie Lin, Apan Dastider, and Sayyed Jaffar Ali Raza
- Subjects
0209 industrial biotechnology ,Computer science ,business.industry ,Bayesian probability ,02 engineering and technology ,Kinematics ,Bayesian inference ,Gait ,020901 industrial engineering & automation ,Prior probability ,0202 electrical engineering, electronic engineering, information engineering ,Reinforcement learning ,Robot ,020201 artificial intelligence & image processing ,Artificial intelligence ,business ,Gradient method - Abstract
In this paper, a reinforcement learning method is presented to generate earthworm-like gaits for a hyperredundant earthworm-like manipulator robot. Partially inspired by human brain’s learning mechanism, the proposed learning framework builds its preliminary belief by first starting with adapting rudimentary gaits governed by a generic kinematic knowledge of undulatory, sidewinding and circular patterns. The preliminary belief is then represented as a prior ensemble to learn new gaits by leveraging apriori knowledge and learning a policy by inferring posterior over prior distribution. While the fundamental idea of incorporating Bayesian learning with reinforcement learning is not new, this paper extends Bayesian actor-critic approach by introducing augmented prior-based directed bias in policy search, aiding in faster parameter learning and reduced sampling requirements. We show results on an in-house built 10-DoF earthworm-like robot that exhibits adaptive development, qualitatively learning different locomotion modes, while given with only rudimentary generic gait behaviors. The results are compared against deterministic policy gradient method (DDPG) for continuous control as the baseline. We show that our proposed method can characterize effective performance over DDPG, and it also achieves faster kinematic indexes in various gaits.
- Published
- 2020
9. Policy Reuse in Reinforcement Learning for Modular Agents
- Author
-
Mingjie Lin and Sayyed Jaffar Ali Raza
- Subjects
business.industry ,Computer science ,Task analysis ,Benchmark (computing) ,State space ,Reinforcement learning ,Robot ,Artificial intelligence ,Modular design ,Layer (object-oriented design) ,Reuse ,business - Abstract
We present reusable policy method for modular reinforcement learning problem in continuous state space. Our method relies on two-layered learning architecture. The first layer partitions the agent’s problem space into n-folds sub-agents that are inter-connected with each other with dexterity identical to original problem. It further learns a local control policy for standalone 1-fold sub-agent. The second layer learns a global policy to reuse ‘already learnt’ standalone local policy over each n sub-agents by sampling local policy with global parameters for each sub-agent—parameterizing local policy independently to approximate non-linear interconnections between sub-agents. We demonstrate our method on simulation example of 12-DOF modular robot that learns maneuver pattern of snake-like gait. We also compare our proposed method against standard single-policy learning methods to benchmark optimality.
- Published
- 2019
10. REVIEW: Aortic Atheromas: Current Concepts and Controversies-A Review of the Literature
- Author
-
Assad Movahed, Thenappan Thenappan, and Jaffar Ali Raza
- Subjects
medicine.medical_specialty ,Transesophageal echocardiogram ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,medicine.artery ,medicine ,Thoracic aorta ,Radiology, Nuclear Medicine and imaging ,In patient ,cardiovascular diseases ,Stroke ,medicine.diagnostic_test ,business.industry ,Warfarin ,Magnetic resonance imaging ,medicine.disease ,body regions ,Aortic atheroma ,cardiovascular system ,Cardiology ,lipids (amino acids, peptides, and proteins) ,Radiology ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
The frequent use of transesophageal echocardiogram (TEE) has led to the increased recognition of aortic atheromas. Retrospective and prospective follow-up studies have reported an association between aortic atheromas and stroke in the high-risk patient population, with complex plaques being more likely to embolize than simple plaques. However, TEE-based studies in the low-risk cohorts have failed to show a similar association. There is growing body of evidence suggesting that aortic atheroma is a marker of generalized atherosclerosis. Although magnetic resonance (MR) imaging and computed tomography (CT) scan are emerging as a powerful noninvasive tool for characterization of aortic atheromas, TEE is the imaging modality of choice. Currently, treatment of aortic atheromas is not well defined, and mixed outcomes have been reported for anticoagulation therapy with warfarin. Statins appear promising based on their plaque stabilization properties. However, there are no randomized control trials to establish the role of both anticoagulation and statins in patients with aortic atheromas, and are warranted in the future.
- Published
- 2007
11. Cell transplantation for treatment of left-ventricular dysfunction due to ischemic heart failure: from bench to bedside
- Author
-
Aravinda Nanjundappa, Wayne E. Cascio, Jaffar Ali Raza, Robert S. Dieter, and Sangeeta Mandapaka
- Subjects
Cardiac Catheterization ,medicine.medical_specialty ,Cell type ,Cell Survival ,Cell Transplantation ,Angiogenesis ,Cell Culture Techniques ,Myocardial Ischemia ,Neovascularization, Physiologic ,Electrocardiography ,Ventricular Dysfunction, Left ,Cell transplantation ,Internal medicine ,Internal Medicine ,medicine ,Animals ,Humans ,Myocytes, Cardiac ,Myocardial infarction ,Potential mechanism ,Bone Marrow Transplantation ,Ventricular Remodeling ,business.industry ,Recovery of Function ,General Medicine ,medicine.disease ,Bench to bedside ,Heart failure ,Cardiology ,Electrophysiologic Techniques, Cardiac ,Cardiology and Cardiovascular Medicine ,business ,Ischemic heart ,Stem Cell Transplantation - Abstract
Cell transplantation is an innovative technology that involves the implantation of a variety of myogenic and angiogenic cell types. The transplanted cells proliferate and augment left ventricular performance and therein ameliorate the heart failure symptoms. The concept of cell transplantation has followed the footsteps of angiogenesis starting as bench side research. The latter half of the decade saw the transformation of this potential mechanism to a promising therapy for ischemic heart failure. More than 150 patients have been treated with cellular transplantation worldwide. This novel application has the potential to revolultionalize alternative therapeutic approaches to management of heart failure.
- Published
- 2007
12. Atrial fibrillation during adenosine pharmacologic stress testing
- Author
-
Assad Movahed, Matthew Cummings, and Jaffar Ali Raza
- Subjects
medicine.medical_specialty ,Adenosine ,Chest pain ,Bronchospasm ,Ventricular Dysfunction, Left ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Sinus rhythm ,Adverse effect ,Aged, 80 and over ,business.industry ,Electroencephalography ,Atrial fibrillation ,Middle Aged ,medicine.disease ,Exercise Test ,cardiovascular system ,Cardiology ,Female ,Supraventricular tachycardia ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Atrioventricular block ,medicine.drug - Abstract
o d in th S g p in h n Adenosine is a naturally occurring nucleoside found roughout the human body. It has both antiarrhythmic nd vasodilatory properties, making it a useful diagnostic nd therapeutic agent in clinical cardiology. Adenosine as been used in the United States since 1989 for the anagement of reentrant supraventricular tachycardia VT) and is considered to be the initial drug of choice r the acute treatment of this frequently encountered rrhythmia. It is also commonly used off label to ifferentiate wide-complex tachycardias and is widely sed as a pharmacologic stress agent in conjunction with yocardial perfusion imaging (MPI). Adenosine has been reported to have an excellent fety profile, and serious adverse effects have been frequently reported. The most commonly encountered dverse effects are flushing, chest pain, and shortness of reath. Far less common, more serious adverse effects clude atrioventricular block, bronchospasm, bradycaria, and hemodynamically significant hypotension. ecause of adenosine’s short half-life, these effects are sually rapidly reversed with the termination of its dministration. Though not generally recognized, atrial fibrillation a potentially serious adverse effect of adenosine that as been reported, particularly when used to treat VT. Silverman et al reported reproducible adenosineduced atrial fibrillation in 5 patients undergoing elecophysiology testing for SVT. Garratt et al reported a ngle case of nonsustained atrial fibrillation in a patient sinus rhythm who received adenosine. Cases of susined atrial fibrillation after adenosine administration ave also been reported by McIntosh-Yellin et al and riffith et al. Atrial fibrillation occurring during adenosine pharacologic stress testing has been far less frequently ported. In fact, atrial fibrillation is not listed as a side
- Published
- 2006
13. Optimal management of hyperlipidemia in primary prevention of cardiovascular disease
- Author
-
Joseph D. Babb, Jaffar Ali Raza, and Assad Movahed
- Subjects
medicine.medical_specialty ,business.industry ,Hyperlipidemias ,Disease ,medicine.disease ,Surgery ,Primary Prevention ,Clinical trial ,Ezetimibe ,Cardiovascular Diseases ,Hyperlipidemia ,medicine ,Life expectancy ,Humans ,cardiovascular diseases ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Young adult ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,Adverse effect ,business ,National Cholesterol Education Program ,Hypolipidemic Agents ,medicine.drug - Abstract
Cardiovascular disease (CVD) in the developed countries continues to grow at an epidemic proportion. There are a significant number of young adults with no clinical evidence of CVD, but who have two or more risk factors that predispose them to CV events and death. Many of these risk factors are modifiable, and by controlling these factors, the CVD burden can be decreased significantly. Recent statistics have shown that, if all major forms of CVD were eliminated, the life expectancy would rise by almost 7 years. Hence it is imperative that primary prevention efforts should be initiated at a young age to avert decades of unattended risk factors. Hyperlipidemia has been linked to CVD almost a century ago. Since then various clinical trials have not only supported this link, but have also shown the CV benefits in aggressively treating patients with hyperlipidemia. In this generation, we have various therapeutic agents that are capable of reducing the elevated lipid levels. With drugs like statins, we are able to reduce the risk of CVD by about 30% and avoid major adverse events. Newer drugs are being researched and introduced in the treatment of hyperlipidemia in humans. These can be used in combination therapy resulting in optimal levels of lipids. The new National Cholesterol Education Program (NCEP)/Adult Treatment Panel III (ATP III) guidelines have come as a wake-up call to clinicians about primary prevention of CVD through strict lipid management and multifaceted risk management approach in the prevention of CVD.
- Published
- 2004
14. Coronary stenting in stable patients: Identification of a low-risk subgroup that may not require adjunctive antiplatelet therapy
- Author
-
Micheal Zellinger, Jaffar Ali Raza, Tift Mann, William N. Newman, Gregory C. Rose, Joel E. Schneider, Laura Raynor, Robert Lee Jobe, Gabriela Cubeddu, Roberto J. Cubeddu, and Josie Bowen
- Subjects
Male ,medicine.medical_specialty ,Ticlopidine ,Abciximab ,medicine.medical_treatment ,Coronary Disease ,Coronary Angiography ,Risk Assessment ,Severity of Illness Index ,Coronary artery disease ,Immunoglobulin Fab Fragments ,Reference Values ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,cardiovascular diseases ,Myocardial infarction ,Angioplasty, Balloon, Coronary ,Aged ,Probability ,Chemotherapy ,business.industry ,Antibodies, Monoclonal ,Coronary stenting ,General Medicine ,medicine.disease ,Clopidogrel ,Combined Modality Therapy ,Survival Analysis ,Surgery ,Diabetes Mellitus, Type 1 ,Treatment Outcome ,Chemotherapy, Adjuvant ,Cardiology ,Female ,Stents ,Cardiology and Cardiovascular Medicine ,business ,Diabetic Angiopathies ,Mace ,Follow-Up Studies ,medicine.drug - Abstract
The present study prospectively evaluated adjunctive antiplatelet therapy in patients without insulin-requiring diabetes during elective coronary stenting. Three hundred patients were randomized to one of three treatment groups: clopidogrel pretreatment, adjunctive abciximab, or control. Stenting was successful in 98% and no deaths occurred. Thirty-day and 1-year major adverse coronary events (MACEs) was similar in all groups. A subgroup of 109 patients undergoing single-vessel stenting of type A/B1 lesions with short guidewire times had no postprocedure myocardial infarction or 30-day MACE. We conclude that patients with these characteristics may safely undergo elective coronary stenting without adjunctive antiplatelet therapy.
- Published
- 2003
15. Use of cardiovascular medications in the elderly
- Author
-
Assad Movahed and Jaffar Ali Raza
- Subjects
Drug ,Aging ,medicine.medical_specialty ,health care facilities, manpower, and services ,media_common.quotation_subject ,Population ,Normal aging ,Disease ,Humans ,Medicine ,Drug Interactions ,Medical prescription ,Intensive care medicine ,education ,Aged ,media_common ,Cause of death ,education.field_of_study ,business.industry ,CARDIOVASCULAR MEDICATIONS ,Cardiovascular Agents ,social sciences ,humanities ,Surgery ,Autonomic nervous system ,Cardiovascular Diseases ,sense organs ,Cardiology and Cardiovascular Medicine ,business - Abstract
Cardiovascular disease is the leading cause of death in patients aged 65 and above. Although elderly persons represent only 12.4% of the US population, they account for about a third of drug expenditures. However the appropriate use of cardiovascular medications in these patients has been shown to reduce the rate of cardiovascular morbidity and mortality. The normal aging and the disease process in the elderly result in significant changes at the structural and molecular level in the elderly. The changes that take place in the autonomic nervous system, the kidneys, and the liver in the elderly modify the metabolism and clinical effects of most medications. Elderly patients are also susceptible to side effects and adverse drug reactions. Physicians should have a clear understanding of the normal aging processes, the abnormal changes due to disease process and the changes in the pharmacology of drugs in the elderly to deliver proper care to the elderly patient.
- Published
- 2002
16. Left main myocardial infarction in a healthy young male—A case report
- Author
-
Jaffar Ali Raza, Rony L. Shammas, Pabitra K. Saha, J.Mark Williams, Assad Movahed, Jaafer Golzar, and Nazim Uddin Azam Khan
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Cardiogenic shock ,Revascularization ,medicine.disease ,Sudden death ,Internal medicine ,cardiovascular system ,medicine ,Cardiology ,Myocardial infarction ,Thrombus ,Cardiology and Cardiovascular Medicine ,business ,Young male ,Coronary atherosclerosis ,Angiology - Abstract
Acute left main coronary artery occlusion is a catastrophic and mostly fatal event. Patients may present with sudden death or cardiogenic shock. Intra-aortic balloon pump support and emergency revascularization is indicated to preserve the left ventricular function. We describe a case of left main thrombus in a health 24-year-old young male with no risk factors for coronary atherosclerosis.
- Published
- 2011
17. ST segment elevation during adenosine pharmacological stress testing in a patient with coronary artery disease
- Author
-
Assad Movahed, Nazim Uddin Azam Khan, Jaffar Ali Raza, and Jamal S Mustafa
- Subjects
medicine.medical_specialty ,Adenosine ,Adenosine A2 Receptor Agonists ,Receptor, Adenosine A2A ,Sinus bradycardia ,medicine.medical_treatment ,Vasodilator Agents ,Myocardial Infarction ,Perfusion scanning ,Coronary Artery Disease ,Article ,Coronary artery disease ,Myocardial perfusion imaging ,Internal medicine ,medicine.artery ,medicine ,Humans ,Myocardial infarction ,Cardiac catheterization ,Aged ,Tomography, Emission-Computed, Single-Photon ,Ejection fraction ,medicine.diagnostic_test ,business.industry ,Myocardial Perfusion Imaging ,General Medicine ,medicine.disease ,Vasodilation ,Right coronary artery ,Cardiology ,Female ,Endothelium, Vascular ,medicine.symptom ,business - Abstract
Case history: a 76-year-old African-American female presented to a community hospital with complaints of chest pain. Her medical history was significant for hypertension, gastroesophageal reflux disease (GERD), hyperlipidemia, and bipolar disorder. On arrival at the emergency department, electrocardiogram showed acute inferior wall myocardial infarction (MI). The patient received thrombolytic therapy with tenecteplase (TNKase™) with successful reperfusion. On arrival at our hospital, the patient denied any chest pain and her electrocardiogram showed sinus bradycardia with small Q-waves in the inferior leads II, III, and AVF (see Figure 1). She was treated with aspirin, heparin, lisinopril, simvastatin, and clopidogrel. Beta-blocker was not started as the patient was having bradycardia. The patient was scheduled to undergo myocardial perfusion scan 48 hours following her uncomplicated inferior wall MI. Figure 1 Initial Electrocardiogram Showing Q-waves in the Inferior Leads At rest, the patient received 12.0mCi of technetium 99msestamibi. Seventy-five minutes later, rest myocardial perfusion images were obtained by non-gated single photon emission computed tomography (SPECT). Then she received adenosine infusion at 140µg/kg/minute for six minutes. Blood pressure and 12-lead electrocardiogram were obtained every minute and the patient’s symptoms were recorded. Resting heart rate was 67. Heart rate three minutes into the adenosine infusion was 73, and heart rate six minutes into the adenosine infusion was 85. Resting blood pressure was 152/69. Blood pressure three minutes into the adenosine infusion was 128/54, and blood pressure six minutes into the adenosine infusion was 70/47. Resting electrocardiogram showed normal sinus rhythm, small inferior Q-waves, and ST–T changes. There was an additional 1–2mm ST segment depression in the electrocardiographic leads I, AVL, and V2, plus 1–3mm additional ST segment elevation was noted in II, III, and AVF during and up to three minutes-post adenosine infusion (see Figure 2). There were occasional premature ventricular complexes and premature atrial complexes before, during, and post-adenosine infusion. The patient did not report chest pain during or after adenosine infusion. Figure 2 Electrocardiogram Obtained During Adenosine Infusion Showing ST Segment Elevation in the Inferior Leads Three minutes into the adenosine infusion, 44mCi of technetium 99m sestamibi was injected intravenously. One hour and 50 minutes later, the stress (adenosine) myocardial perfusion images were obtained by gated SPECT. SPECT images were acquired with a dual-head gamma camera using the step-and-shoot detector rotation, obtaining 32 projections over 180° arcs (45° right anterior oblique to 45° left posterior oblique). The camera was equipped with a low-energy, high-resolution collimator. Rest and stress images were acquired with a 20% window centered over the 140KeV photo peak. Gated acquisitions were obtained using eight frames per cardiac cycle with a 40% acceptance window. Acquisition times were 40 seconds per projection. The summed projection data sets were filtered with a butterworth filter (order 5 cut-off 0.33). Short-, vertical-, long-, and horizontal-axis images were evaluated for transient, partially reversible, and fixed perfusion defects. The rest and stress (adenosine) myocardial perfusion images revealed normal-sized left ventricle and mild to moderate transient myocardial perfusion defect (mild to moderate ischemia) superimposed on mild fixed myocardial perfusion defect (superimposed on mild scar) involving the inferior, inferoapex, and inferolateral wall of the left ventricle (see Figure 3). There were hypokinetic inferior, inferoapex, and inferolateral walls of the left ventricle, with resting global left ventricular ejection fraction (LVEF) of 40%. The right ventricle was normal in size and function. Figure 3 Stress Myocardial Perfusion Polar Map Depicting Flow Defect in the Region of the Right Coronary Artery Following the adenosine myocardial perfusion scanning, the patient underwent cardiac catheterization. Cardiac catheterization showed normal left main, left anterior descending, and circumflex arteries. The right coronary artery showed a 75% stenosis in the mid segment (see Figure 4). The patient had a 3.5×16mm stent deployed without any complications. Her post-procedure course in the hospital was uneventful and she was discharged the following day in a stable condition. Figure 4 Left Anterior Oblique View of the Right Coronary Artery
- Published
- 2010
18. Echocardiography and Contrast Echocardiography
- Author
-
Firas A. Ghanem, Ishtiaque H. Mohiuddin, Jaffar Ali Raza, and Assad Movahed
- Subjects
Ultrasound beam ,medicine.diagnostic_test ,business.industry ,Infective endocarditis ,Contrast echocardiography ,medicine ,Ultrasound wave ,Doppler echocardiography ,medicine.disease ,Nuclear medicine ,business - Abstract
In 1953, Dr. Helmut Hertz of Sweden together with Dr. Inge Edler began to use a commercial ultrasonoscope to examine the heart, thus starting the era of clinical echocardiography [1].
- Published
- 2008
19. Clinical Cardiac Electrophysiology – An Overview
- Author
-
Jaffar Ali Raza, Assad Movahed, R. Wayne Kreeger, and Senthil Thenappan
- Subjects
medicine.medical_specialty ,Conduction abnormalities ,Mechanism (biology) ,business.industry ,Cardiac electrophysiology ,medicine.medical_treatment ,Cardiac resynchronization therapy ,Subspecialty ,medicine.disease ,Internal medicine ,cardiovascular system ,Cardiology ,Clinical electrophysiology ,Medicine ,cardiovascular diseases ,medicine.symptom ,business ,Atrial tachycardia ,Brugada syndrome - Abstract
Clinical cardiac electrophysiology is a subspecialty of cardiology dealing with the evaluation and management of patients with complex rhythm or conduction abnormalities. In the last four decades, clinical cardiac electrophysiology has evolved into an established discipline credited with improving and saving hundreds of thousands of lives. We briefly review the basic electrophysiologic principles, anatomy of the electric system of the heart, mechanism of arrhythmias, genetical predisposition to arrhythmias, types of arrhythmias, diagnostic electrophysiologic studies, and pharmacologic and device therapies available for the treatment of different types of arrhythmias.
- Published
- 2008
20. Myocardial Perfusion Scintigraphy in the Assessment of Post-Revascularization – Current Status and Limitations
- Author
-
Jaffar Ali Raza and Assad Movahed
- Subjects
medicine.medical_specialty ,Percutaneous ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,Revascularization ,medicine.disease ,Coronary artery disease ,Myocardial perfusion imaging ,surgical procedures, operative ,medicine.anatomical_structure ,Restenosis ,Conventional PCI ,medicine ,cardiovascular diseases ,Radiology ,business ,Artery - Abstract
Myocardial perfusion imaging (MPI) is widely utilized in the non-invasive diagnosis and management of coronary artery disease (CAD). Radionuclide MPI has been well studied in the evaluation, risk stratification and identification of patients with CAD who will benefit from revascularization. Myocardial revascularization using percutaneous coronary interventions (PCI) and coronary artery bypass graft (CABG) has become a mainstay in the treatment of patients with CAD. The idea of performing a functional study after revascularization is to identify the areas that are not revascularized or to look for restenosis and progression of native vessel disease or disease in the grafts.
- Published
- 2008
21. Cardiovascular Medications: Pharmacokinetics and Pharmacodynamics
- Author
-
Jaffar Ali Raza, Assad Movahed, and R. Wayne Kreeger
- Subjects
medicine.medical_specialty ,business.industry ,CARDIOVASCULAR MEDICATIONS ,medicine.medical_treatment ,Developing country ,Disease ,Urbanization ,medicine ,Smoking cessation ,Intensive care medicine ,business ,Developed country ,Disease burden ,Cause of death - Abstract
Cardiovascular diseases (CVD) have reached epidemic proportions in developed countries, and are the leading cause of morbidity and mortality. An estimated 16.7 million – or 29.2% of total global deaths – result from the various forms of CVD, many of which are preventable by healthy diet, regular physical activity, and smoking cessation [1]. CVD is no longer the disease of the developed world: some 80% of all CVD deaths worldwide took place in developing, low and middle-income countries and these countries also account for 86% of the global CVD disease burden. By 2010, CVD will be the leading cause of death in developing countries. The rise in CVD reflects a significant change in diet habits, physical activity levels, and tobacco consumption worldwide as a result of industrialization, urbanization, economic development and food market globalization. To deal with this changing situation, an extraordinary array of new cardiovascular therapies continues to become available. These drugs and therapies are efficacious and are better tolerated than their predecessors, not only in the management but also in prevention of CVD. This results in ever more difficulty for the practitioners of medicine in understanding the mechanism of action of these medications and also in deciding the proper medication for their patients. This chapter is a concise presentation of the pharmacology of cardiovascular medications.
- Published
- 2008
22. Aortic atheromas: current concepts and controversies-a review of the literature
- Author
-
Thenappan, Thenappan, Jaffar, Ali Raza, and Assad, Movahed
- Subjects
Diagnostic Imaging ,Stroke ,Risk Factors ,Aortic Diseases ,Anticoagulants ,Humans ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Atherosclerosis ,Echocardiography, Transesophageal - Abstract
The frequent use of transesophageal echocardiogram (TEE) has led to the increased recognition of aortic atheromas. Retrospective and prospective follow-up studies have reported an association between aortic atheromas and stroke in the high-risk patient population, with complex plaques being more likely to embolize than simple plaques. However, TEE-based studies in the low-risk cohorts have failed to show a similar association. There is growing body of evidence suggesting that aortic atheroma is a marker of generalized atherosclerosis. Although magnetic resonance (MR) imaging and computed tomography (CT) scan are emerging as a powerful noninvasive tool for characterization of aortic atheromas, TEE is the imaging modality of choice. Currently, treatment of aortic atheromas is not well defined, and mixed outcomes have been reported for anticoagulation therapy with warfarin. Statins appear promising based on their plaque stabilization properties. However, there are no randomized control trials to establish the role of both anticoagulation and statins in patients with aortic atheromas, and are warranted in the future.
- Published
- 2008
23. Current concepts of cardiovascular diseases in diabetes mellitus
- Author
-
Jaffar Ali Raza and Assad Movahed
- Subjects
Male ,medicine.medical_specialty ,Population ,Coronary Artery Disease ,Sudden death ,Coronary artery disease ,Diabetes Complications ,Sex Factors ,Risk Factors ,Internal medicine ,Diabetes mellitus ,medicine ,Diabetes Mellitus ,Myocardial Revascularization ,Humans ,Mass Screening ,cardiovascular diseases ,Endothelial dysfunction ,education ,Metabolic Syndrome ,education.field_of_study ,Aspirin ,business.industry ,medicine.disease ,Obesity ,Surgery ,Cardiovascular Diseases ,Female ,Metabolic syndrome ,Cardiology and Cardiovascular Medicine ,business ,Dyslipidemia ,Diabetic Angiopathies ,Platelet Aggregation Inhibitors - Abstract
The incidence of diabetes has reached epidemic proportions across the world. In patients with diabetes, there is a two to four times increased risk of developing coronary artery disease (CAD). Diabetes seems to eliminate the protective benefits of hormones in women against CAD. Patients with type II diabetes also have hypertension, dyslipidemia, obesity, endothelial dysfunction and prothrombotic factors, called 'the metabolic syndrome'. Not only the incidence of CAD is higher in diabetes, the mortality of the diabetic patients after a cardiac event is significantly increased as compared to non-diabetics, including sudden death. Although in the past 35 years there has been a decline in the rate of death due to CAD in the general population, this has not been seen among patients with diabetes. Primary prevention can play an important role in decreasing the incidence of CAD in diabetic patients. Aggressive treatment of hyperlipidemia and hypertension is essential. Recent knowledge about the protective effects of aspirin, statins, angiotension converting enzyme inhibitors, and glitazones in the diabetic patients, if used appropriately will go a long way in primary and secondary prevention of CAD in patients with diabetes.
- Published
- 2003
24. Transradial management of saphenous vein bypass graft disease using rheolytic thrombectomy and coronary stenting
- Author
-
Tift, Mann, Jaffar Ali, Raza, C H, Whitlock, and Michael, Arrowood
- Subjects
Male ,Blood Vessel Prosthesis Implantation ,Ventricular Dysfunction, Left ,Coronary Stenosis ,Humans ,Saphenous Vein ,Stents ,Coronary Artery Bypass ,Aged ,Thrombectomy - Abstract
We report a case of successful treatment of a severely diseased saphenous vein graft from the transradial approach. Initial rheolytic thrombectomy was performed followed by coronary stenting through a 6 French guide catheter. Continuing miniaturization of interventional devices increases the utility of the transradial approach.
- Published
- 2003
25. Ischemic heart disease in women and the role of hormone therapy
- Author
-
Jaffar Ali Raza, Assad Movahed, and Richard A Reinhart
- Subjects
Selective Estrogen Receptor Modulators ,medicine.medical_specialty ,Heart disease ,medicine.medical_treatment ,Myocardial Ischemia ,Contraceptives, Oral, Hormonal ,Sex Factors ,Risk Factors ,Diabetes mellitus ,Internal medicine ,medicine ,Animals ,Humans ,cardiovascular diseases ,Risk factor ,Progesterone ,Cause of death ,medicine.diagnostic_test ,business.industry ,Estrogen Replacement Therapy ,Hormone replacement therapy (menopause) ,Estrogens ,medicine.disease ,Endocrinology ,Blood pressure ,Female ,Hormone therapy ,Cardiology and Cardiovascular Medicine ,business ,Lipid profile - Abstract
The prevalence of ischemic heart disease (IHD) has been increasing among the women in developed countries. The well recognized IHD excess in men has often obscured the fact that IHD is the leading cause of death in women. Women have atypical symptoms of IHD that lead to a delay in the diagnosis and an overall poor prognosis. Women have a delay in the onset of IHD due to the beneficial effects of their sex hormones. Postmenopausal women lose this beneficial effect of estrogen and undergo significant changes in their lipid profile, arterial pressure, glucose tolerance, and vascular reactivity that increase their risk for development of IHD. Recently there has been considerable interest in the sex hormones and their role in IHD in women. The general belief that hormone replacement therapy (HRT) has an overall beneficial effect on cardiovascular disease (CVD) in women and hence decreases CVD mortality and morbidity has not been shown in the recent multicenter prospective studies. With the availability of various types of estrogen and progestins, physicians prescribing these agents should take into consideration their varying effects on the cardiovascular system. Risk factor modifications should include diet, weight loss, regular exercise, smoking cessation and adequate control of hypertension (HTN), diabetes (DM) and hyperlipidemia. In the appropriate setting, treatment with proven beneficial agents like aspirin, beta-blockers, angiotensin converting enzyme (ACE) inhibitors and statins will help decrease the burden of IHD in women.
- Published
- 2003
26. Pharmacological stress agents for evaluation of ischemic heart disease
- Author
-
Jaffar Ali Raza, Williams C Reeves, and Assad Movahed
- Subjects
Diagnostic Imaging ,medicine.medical_specialty ,Vasodilator Agents ,Ischemia ,Myocardial Ischemia ,Hemodynamics ,Disease ,Coronary artery disease ,Catecholamines ,Internal medicine ,Dobutamine ,medicine ,Humans ,Cause of death ,business.industry ,Adrenergic beta-Agonists ,medicine.disease ,Arbutamine ,Dipyridamole ,Cardiology ,Exercise Test ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug ,Forecasting - Abstract
Ischemic heart disease is the leading cause of death in the developed countries for those older than 65 years of age. In patients suspected to have coronary artery disease a stress test should be performed to identify the vulnerability of the myocardium to ischemia. As a rule of thumb, the evaluation of coronary artery disease is best done by exercise stress test. In patients who are not able to exercise adequately, pharmacological stress agents are used. The commonly used agents are the coronary vasodilators, adenosine and dipyridamole and the catecholamines, dobutamine and arbutamine. These agents are combined with imaging techniques to increase the sensitivity and specificity of the test. These agents have been widely used and have an excellent safety profile. Another advantage in using pharmacological stress agents is that they do not affect the image quality, especially with echocardiography and magnetic resonance imaging. Ongoing developments hold promise for safer and more reliable pharmacological stress agents in the future.
- Published
- 2001
27. Coronary stenting in stable patients: Identification of a low-risk subgroup that may not require adjunctive antiplatelet therapy.
- Author
-
Tift Mann, Roberto J. Cubeddu, Laura Raynor, Josie Bowen, Joel E. Schneider, Gregory Rose, Gabriela Cubeddu, Jaffar Ali Raza, Robert Lee Jobe, William Newman, and Micheal Zellinger
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.